bioMerieux (OTCMKTS:BMXMF) Sets New 52-Week Low – Time to Sell?

bioMerieux (OTCMKTS:BMXMF) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as $111.10 and last traded at $111.10, with a volume of 125 shares changing hands. The stock had previously closed at $125.06.

Analysts Set New Price Targets

Separately, Exane BNP Paribas lowered bioMerieux to a “neutral” rating in a research report on Wednesday, January 28th. Two investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

bioMerieux Trading Down 8.4%

The stock has a fifty day moving average price of $124.85 and a 200 day moving average price of $131.53. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.30 and a current ratio of 2.27.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.